The Vanguard Group, Inc. has recently announced that it has increased stake in Xeris Biopharma Holdings Inc. (NASDAQ:XERS) by 3.81%. After grabbing 6.59 million shares, the institutional investor is now in possession of 0.24 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.80% having worth around $14.9 million. Moreover, Geode Capital Management LLC increased its share by 97994.0 to have a control over 2.53 million shares. And SSgA Funds Management, Inc. raised its holdings to 0.14 million shares by acquiring 2.28 million shares or 1.66% of the stake.
Xeris Biopharma Holdings Inc. (XERS) concluded trading on 05/25/23 at a closing price of $2.84, with 0.94 million shares of worth about $2.68 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 123.62% during that period and on Thursday the price saw a loss of about -1.05%. Currently the company’s common shares owned by public are about 137.14M shares, out of which, 132.35M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $6.00 and could fall to a lowest price of $4.00. The stock’s current price level is 43.2% above of average price target set by the analysts, while a rise to estimated low would result in gain of 29.0% for the stock. However, touching the estimated high of $6.00 would mean a gain of 52.67% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 15 times over the past 12 months. They bought 3,060,000 shares in 15 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
Vanguard Total Stock Market ETF, iShares Russell 2000 ETF, and Invesco Global Opportunities Fund are the top 3 mutual funds which are holding stakes in Xeris Biopharma Holdings Inc. Vanguard Total Stock Market ETF is currently holding 4.11 million shares of worth totaling $9.28 million. The company recently came buying 0.0 shares which brought its stake up to 2.99% of the company’s outstanding shares. iShares Russell 2000 ETF sold 40960.0 shares, after which its hold over company’s outstanding shares shrunk to 2.04%, leaving 2.8 million shares with the mutual fund that have a worth of about $6.33 million. Invesco Global Opportunities Fund, after buying 2.0 million shares, have now control over 1.46% of the stake in the company. It holds 0.0 shares of worth $4.52 million.
However, the stock later moved at a day high price of 2.8800, or with a loss of -1.05%. Stock saw a price change of 1.07% in past 5 days and over the past one month there was a price change of 30.88%. Year-to-date (YTD), XERS shares are showing a performance of 113.53% which increased to 44.90% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.97 but also hit the highest price of $3.03 during that period. The average intraday trading volume for Xeris Biopharma Holdings Inc. shares is 1.34 million. The stock is currently trading 7.35% above its 20-day simple moving average (SMA20), while that difference is up 33.51% for SMA50 and it goes to 77.01% higher than SMA200.
The Vanguard Group, Inc. acquired 6.59 million shares of Xeris Biopharma Holdings Inc. having value of about $14.9 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 0.24 million shares in the company valued at close to $686518.88, or have control over 3.81% stake in the company. Xeris Biopharma Holdings Inc. (NASDAQ: XERS) currently have 137.14M outstanding shares and institutions hold larger chunk of about 45.50% of that. Holding of mutual funds in the company is about 22.47% while other institutional holders and individual stake holders have control over 4.89% and 15.77% of the stake respectively.
The stock has a current market capitalization of $377.81M and its 3Y-monthly beta is at 1.30. It has posted earnings per share of -$0.57 in the same period. It has Quick Ratio of 1.70 while making debt-to-equity ratio of 6.25. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for XERS, volatility over the week remained 5.43% while standing at 6.77% over the month.
Analysts are in expectations that Xeris Biopharma Holdings Inc. (XERS) stock would likely to be making an EPS of -$0.13 in the current quarter, while forecast for next quarter EPS is -$0.11 and it is -$0.28 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.15 which is -$0.11 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.19 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 55.10% while it is estimated to increase by 40.40% in next year.
Analysts at 4 brokerage firms have issued recommendations for the Xeris Biopharma Holdings Inc. (XERS)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.50. Out of those 4 Wall Street analysts, 4 recommended a “Buy” rating, while 0 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Leave a Reply